Percardia Inc. Presents at Emerging Medical Technologies West Conference and Announces Appointment of Vice President Clinical Affairs
Boston, MA, March 6, 2000/PRNewswire/... Percardia Inc., a privately-held medical device company focused on the development of new therapeutic interventions for the treatment of coronary artery disease, announced today at the Emerging Medical Technologies West Conference the appointment of Michail Pankratov MD, PhD, as Vice President of Clinical Affairs.
Dr. Pankratov brings to Percardia a combination of both academic and industry experience. Over the past two decades, Dr. Pankratov has distinguished himself in the field of medical research where he has authored or co-authored over 70 publications. Most recently, he was VP Clinical & Consumer Affairs at Palomar Medical Technologies. Previously, he served as VP Clinical Affairs for Vista Medical Technologies, CardioThoracic Surgery Division, and was involved in the development, testing and implementation of advanced visualization systems for cardiac surgery.
Michail was born and raised in Russia where he attended medical school. He holds a Masters Degree from MIT and a PhD from Northeastern University in Engineering.
"We are pleased to announce today that Dr. Michail Pankratov has joined our senior management team at Percardia. His skills and experience in scientific research and clinical trials coupled with his expertise in engineering make for a valuable addition to our development and clinical efforts with the VCAB Surgical Delivery System," said Nancy Briefs, President and Chief Executive Officer of Percardia, at EMT West. EMT West is a two-day forum in which early-stage companies present tomorrow's most exciting technologies to an audience of over 300 executives. The forum focuses on advanced technologies for today's most important growth markets, including cardiovascular therapeutics.
Percardia's proprietary advanced technology, VCAB ventricle to coronary artery bypass system, is based on intellectual property licensed from Dr. Peter Wilk, a noted surgeon and inventor. The device creates a channel from the left ventricle of the heart to the coronary artery creating an entirely novel method of delivering blood. The company, located in Nashua, New Hampshire, is in early-stage development of the devices and is backed by several leading investors including Atlas Venture, Crescendo Ventures, Medtronic Inc. and Vanguard Venture Partners.